



For Immediate Release

OMNIA BIOLOGICS AND LENTIGEN SIGN MANUFACTURING AGREEMENT

(August 15, 2005 – Rockville, MD) Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and Lentiviral vector manufacturer Lentigen Corp. (Baltimore, MD) today announced signing of a master services agreement for Omnia to provide Lentigen with access to its cGMP facilities and services.

Omnia Biologics (Omnia) is a contract manufacturer focused on clinical trials material manufacture of innovative biopharmaceuticals. Lentigen is a contract manufacturer of research and clinical grade Lentiviral vectors.

Dale VanderPutten, CEO, Omnia Biologics, Inc commented on the deal “Combining Dr. Dropulic and his team’s leadership and vast experience in Lentiviral vector technology and Omnia’s capacity and capabilities to produce cGMP clinical trial materials focused on servicing the needs of novel bio-pharma drug developers, is a great step forward in providing a vital service to the developers of this new and exciting drug platform as well as the patients who will benefit from these advances.”

Boro Dropulic, CEO, Lentigen Corporation commented “We are very pleased to work with Mr VanderPutten and his highly experienced team at Omnia Biologics. Omnia Biologics is one of several partnerships Lentigen is attracting for development of its Lentiviral vector gene delivery platform technology. Omnia Biologics provides Lentigen manufacturing facilities and expertise for the production of clinical grade Lentiviral vector material.”

About Omnia Biologics: (www.omniabiologics.com)

Omnia offers services in the areas of process development, GMP manufacture, and fill-finish for preclinical and Phase I clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.

About Lentigen: (www.lentigen.com)

Lentigen Corporation is a provider of Lentiviral Vector gene delivery and expression solutions. Lentigen manufactures research and clinical grade Lentiviral vectors using unique proprietary technology. The company welcomes establishing relationships with academic institutions and

biopharmaceutical companies that require highly efficient and stable gene delivery solutions for their specific applications.

###

CONTACT:

Omnia Biologics, Inc. 12115-D Parklawn Drive, Rockville, Maryland, 20852, USA, Dale VanderPutten, Chief Executive Officer, E-mail: dale@omniabiologics.com, Tel: 301-984-5928, Fax 301-984-2515. Lentigen Corporation 1450 South Rolling Road, Baltimore, Maryland 21227 USA, Dr. Boro Dropulic boro.dropulic@Lentigen.com, Tel. 443 543 5300, Fax 443 543 5301.